FoundationOne Liquid CDx approved for Tepmetko
Nov. 21, 2024—Foundation Medicine announced it has received approval from the FDA for FoundationOne Liquid CDx to be used as a companion diagnostic for tepotinib (Tepmetko, EMD Serono).
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
FDA OKs Kisqali in people with HR+/HER2- early breast cancer
November 2024—Novartis announced FDA approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.
Qiagen expands agreement with AstraZeneca
November 2024—Qiagen has expanded its master collaboration agreement with AstraZeneca to develop and commercialize companion diagnostics for therapies being developed by AstraZeneca to address chronic diseases.
FDA clears T2 Biosystems Candida panel for pediatric patients
November 2024—T2 Biosystems announced FDA clearance of its T2Candida panel for pediatric patients.
Verichem chemistry reference materials
November 2024—Verichem Laboratories offers multianalyte, multilevel, and liquid-stable Matrix Plus chemistry reference materials for the calibration verification of chemistry assays.
MMQCI releases Xpert PML-RARA linearity, control materials
November 2024—Maine Molecular Quality Controls has launched reference materials for the Cepheid Xpert PML-RARA assay.
Randox now offers Olink panels
November 2024—Randox now offers Olink dual-antibody recognition and proximity extension assay (PEA) technology, bringing the Olink Explore, Target, and Flex panels in-house to accelerate highly specific multiplex biomarker screening.
Illumina unveils MiSeq i100 series benchtop sequencers
November 2024—Illumina has unveiled its MiSeq i100 series of sequencing systems, the MiSeq i100 and MiSeq i100 Plus.
Biofidelity launches Aspyre lung reagents
November 2024—Biofidelity announced the launch of its Aspyre Lung reagents for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer biomarkers in DNA and RNA from tissue and blood in a single, four-step workflow and runs on existing qPCR platforms.
Pillar launches OncoReveal Nexus NGS assay
November 2024—Pillar Biosciences has announced the global launch of OncoReveal Nexus, a research use only next-generation sequencing kit designed to assess key driver genes for hematological and solid tumor malignancies in one multiplex reaction.